532977-52-9Relevant academic research and scientific papers
CC chemokine receptor-3 (CCR3) antagonists: Improving the selectivity of DPC168 by reducing central ring lipophilicity
Pruitt, James R.,Batt, Douglas G.,Wacker, Dean A.,Bostrom, Lori L.,Booker, Shon K.,McLaughlin, Erin,Houghton, Gregory C.,Varnes, Jeffrey G.,Christ, David D.,Covington, Maryanne,Das, Anuk M.,Davies, Paul,Graden, Danielle,Kariv, Ilona,Orlovsky, Yevgeniya,Stowell, Nicole C.,Vaddi, Krishna G.,Wadman, Eric A.,Welch, Patricia K.,Yeleswaram, Swamy,Solomon, Kimberly A.,Newton, Robert C.,Decicco, Carl P.,Carter, Percy H.,Ko, Soo S.
, p. 2992 - 2997 (2008/02/05)
DPC168, a benzylpiperidine-substituted aryl urea CCR3 antagonist evaluated in clinical trials, was a relatively potent inhibitor of the 2D6 isoform of cytochrome P-450 (CYP2D6). Replacement of the cyclohexyl central ring with saturated heterocycles provid
PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS
-
Page/Page column 165-166, (2008/06/13)
The present invention provides compounds of formula (I); and pharmaceutically acceptable salts thereof. The formula (I) compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula (I) compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
Asymmetric synthesis of a new helix-forming β-amino acid: trans-4-aminopiperidine-3-carboxylic acid
Schinnerl, Marina,Murray, Justin K.,Langenhan, Joseph M.,Gellman, Samuel H.
, p. 721 - 726 (2007/10/03)
We report a synthesis of a protected derivative of trans-4aminopiperidine-3-carboxylic acid (APiC). The route provides either enantiomer. All intermediates are purified by crystallization, and large-scale preparation is therefore possible. An analogous ro
